氯雷他定联合匹多莫德对反复呼吸道感染患儿的临床疗效及免疫功能的影响  

Clinical Efficacy of Loratadine Combined with Pidotimod in the Treatment of Children with Recurrent Respiratory Tract Infection and Effect on Immune Function

作　　者：何烁[1] 洪怡[2] 

机构地区：[1]江山市妇幼保健院儿科,浙江江山324100 [2]杭州市第三人民医院儿科

出　　处：《中国药师》2015年第11期1904-1906,共3页China Pharmacist

摘　　要：目的:观察氯雷他定联合匹多莫德对儿童反复呼吸道感染的临床疗效及患儿免疫功能的影响。方法:78例反复呼吸道感染患儿随机分为对照组(n=39)和观察组(n=39)。两组患儿均给予常规对症治疗。对照组加用匹多莫德治疗,观察组在对照组基础上再加用氯雷他定。疗程均为8周。比较两组临床疗效、临床症状和体征改善情况、免疫功能指标水平变化及不良发生情况。结果:观察组总有效率显著高于对照组(P<0.05);观察组治疗后肺部啰音消失时间、扁桃体肿大消退时间、咳嗽消失时间、退热时间均显著短于对照组(P<0.05);治疗后两组Ig G、Ig M、Ig A水平均较治疗前显著降低(P<0.05),CD3+、CD4+、CD4+/CD8+则较治疗前显著增加(P<0.05);且观察组各项免疫指标水平均明显优于对照组(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:氯雷他定联合匹多莫德对儿童反复呼吸道感染的临床疗效显著,能迅速改善患儿临床症状和体征,显著提高患儿免疫功能。Objective：To study the clinical efficacy of loratadine combined with pidotimod in the treatment of children with repeat-ed respiratory tract infection and the effect of the combination on immune function. Methods：Totally 78 cases of patients with repeated respiratory tract infection were randomly divided into the observation group （ n=39 ） and the control group （ n =39 ） . Both of the groups were treated with the routine correct treatment, and the control group was treated with pidotimod and the observation group was treated with loratadine combined with pidotimod with the treatment course of 8 weeks. The clinical efficacy, clinical symptoms, signs improvements, changes of immune function markers level and incidence of adverse drug reactions between the two groups were observed and compared. Results：The total effective rate of the observation group was significantly higher than that of the control group （ P〈0. 05）;the disappearance time of pulmonary rales and cough, fading time of tonsil swelling and fever clearing time of the observation group were significantly shorter than those of the control group（P〈0. 05）. After the treatment, the levels of IgG, IgM and IgA in both groups were significantly lower than those before the treatment （P 〈0.05）; the levels of CD3 ＋, CD4 ＋ and CD4 ＋ /CD8 ＋ in both groups were significantly higher than those before the treatment （P〈0. 05）;the levels of immune indices in the observation group were significantly better than those in the control group（P〈0. 05）. Comparing with the incidence of adverse drug reactions in the control group, no significant difference was shown in the observation group （P〉0. 05）. Conclusion：The clinical efficacy of loratadine com-bined with pidotimod in the treatment of children with repeated respiratory tract infection is effective, which can improve the clinical symptom and signs and enhance the immune function of children significantly.

关 键 词：氯雷他定 匹多莫德 反复呼吸道感染 疗效 免疫功能 

分 类 号：R979.5[医药卫生—药品]